Editorial: Transplantation and cellular therapy in lymphomas and plasma cell disorders by Saad Z. Usmani, Nilanjan Ghosh, Peter Voorhees, Edward Copelan

Get full text

P907: CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS OF THE CANDO... by H. Quach, X. Leleu, M.-V. Mateos, S. Z. Usmani, A. K. Nooka, A. Goldrick, R. Najdi, N. Shu, T. Facon

Get full text

Global disparities in patients with multiple myeloma: a rapid evidence assessment by Maria-Victoria Mateos, Sikander Ailawadhi, Luciano J. Costa, Shakira J. Grant, Lalit Kumar, Mohamad Mohty, Didem Aydin, Saad Z. Usmani

Get full text

Addressing the disparities: the approach to the African American patient with multiple myeloma by Manisha Bhutani, Brandon J. Blue, Craig Cole, Ashraf Z. Badros, Saad Z. Usmani, Ajay K. Nooka, Leon Bernal-Mizrachi, Joseph Mikhael

Get full text

Gene interaction network analysis in multiple myeloma detects complex immune dysregulation associated with shorter survival by Anish K. Simhal, Kylee H. Maclachlan, Rena Elkin, Jiening Zhu, Larry Norton, Joseph O. Deasy, Jung Hun Oh, Saad Z. Usmani, Allen Tannenbaum

Get full text

High WEE1 expression is independently linked to poor survival in multiple myeloma by Anish K. Simhal, Ross S. Firestone, Jung Hun Oh, Viswatej Avutu, Larry Norton, Malin Hultcrantz, Saad Z. Usmani, Kylee H. Maclachlan, Joseph O. Deasy

Get full text

Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4 by Doris K. Hansen, Xiaoxiao Lu, Omar Castaneda Puglianini, Sonja Sorensen, Saad Z. Usmani, Eileen Zhang, Stephen Huo, Yan Zhang, Zaina P. Qureshi, Sundar Jagannath

Get full text

Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents by Saad Z. Usmani, Christoph Heuck, Alan Mitchell, Jackie Szymonifka, Bijay Nair, Antje Hoering, Yazan Alsayed, Sarah Waheed, Sajjad Haider, Alejandro Restrepo, Frits Van Rhee, John Crowley, Bart Barlogie

Get full text

Extrapolation of Survival Data Using a Bayesian Approach: A Case Study Leveraging External Data from Cilta-Cel Therapy in Multiple Myeloma by Stephen Palmer, Yi Lin, Thomas G. Martin, Sundar Jagannath, Andrzej Jakubowiak, Saad Z. Usmani, Nasuh Buyukkaramikli, Hilary Phelps, Rafal Slowik, Feng Pan, Satish Valluri, Lida Pacaud, Graham Jackson

Get full text

P972: INDIRECT COMPARISON OF TECLISTIMAB IN MAJESTEC-1 VERSUS PHYSICIAN’S CHOICE OF THERAPY IN LONG-TERM FOLLOW-UP OF TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA IN D... by K. Weisel, A. Chari, S. Z. Usmani, H. Goldschmidt, M.-V. Mateos, K. Qi, A. Londhe, S. Nair, X. Lin, L. Pei, E. Ammann, R. Kobos, J. Smit, T. Parekh, M. Slavcev, P. Moreau

Get full text

P881: DURABILITY OF RESPONSES WITH BIWEEKLY DOSING OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA ACHIEVING A CLINICAL RESPONSE IN THE MAJESTEC-1 STUDY by Manisha Bhutani, Alfred Garfall, Katarina Uttervall, Saad Z Usmani, Lionel Karlin, Lotfi Benboubker, Hareth Nahi, Jesús San Miguel, Danielle Trancucci, Keqin Qi, Tara Stephenson, Alfredo Perales-Puchalt, Katherine Chastain, Ajai Chari

Get full text

Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma by Xenofon Papanikolaou, Jackie Szymonifka, Adam Rosenthal, Christoph J. Heuck, Alan Mitchell, Donald Johann, Jason Keller, Sarah Waheed, Saad Z. Usmani, Frits Van Rhee, Clyde Bailey, Nathan Petty, Antje Hoering, John Crowley, Bart Barlogie

Get full text

Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study by Niels W. C. J. van de Donk, Nizar Bahlis, Luciano J. Costa, María-Victoria Mateos, Ajay K. Nooka, Aurore Perrot, Alfred L. Garfall, Pragya Thaman, Keqin Qi, Clarissa Uhlar, Katherine Chastain, Margaret Doyle, Saad Z. Usmani

Get full text

Ex vivo efficacy of BCMA‐bispecific antibody TNB‐383B in relapsed/refractory multiple myeloma by David M. Foureau, Manisha Bhutani, Myra Robinson, Fei Guo, Duy Pham, Ben Buelow, Nury Steuerwald, Katherine Rigby, Elise Tjaden, Marina Leonidas, Barry A. Paul, Shebli Atrash, Ami Ndiaye, James T. Symanowski, Peter M. Voorhees, Saad Z. Usmani

Get full text

P933: DARATUMUMAB (D) IN COMBINATION WITH VD OR D-RD IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF CASTOR AND POLLUX STUDIES IN PATIENTS WITH EARLY OR LATE RELAP... by A. Spencer, P. Moreau, M.-V. Mateos, H. Goldschmidt, K. Suzuki, M.-D. Levin, P. Sonneveld, S.-S. Yoon, S. Z. Usmani, K. Weisel, D. Reece, T. Ahmadi, H. Pei, W. Garvin Mayo, X. Gai, J. Carey, R. Carson, M. A. Dimopoulos

Get full text

S184: EVALUATING TECLISTAMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA FOLLOWING EXPOSURE TO OTHER B-CELL MATURATION ANTIGEN (BCMA)-TARGETED AGENTS by C. Touzeau, A. Krishnan, P. Moreau, A. Perrot, S. Z. Usmani, S. Manier, M. Cavo, C. Martinez-Chamorro, A. Nooka, T. Martin, L. Karlin, X. Leleu, N. Bahlis, B. Besemer, L. Pei, R. Verona, S. Girgis, C. Uhlar, R. Kobos, A. Garfall

Get full text

Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma by Amrita Krishnan, Ajay K Nooka, Ajai Chari, Alfred L Garfall, Thomas G Martin, Sandhya Nair, Xiwu Lin, Keqin Qi, Anil Londhe, Lixia Pei, Eric Ammann, Rachel Kobos, Jennifer Smit, Trilok Parekh, Alexander Marshall, Mary Slavcev, Saad Z Usmani

P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF T... by T. Facon, S. K. Kumar, T. Plesner, P. Moreau, N. Bahlis, H. Goldschmidt, M. O’Dwyer, A. Perrot, C. P. Venner, K. Weisel, J. R. Mace, N. Raje, M. Tiab, M. Macro, L. Frenzel, X. Leleu, H. Pei, F. Borgsten, S. Z. Usmani

Get full text

S177: EVALUATING SERUM FREE LIGHT CHAIN RATIO AS A BIOMARKER FOR MULTIPLE MYELOMA by T. Akhlaghi, K. Maclachlan, N. Korde, S. Mailankody, A. Lesokhin, H. Hassoun, S. X. Lu, D. Patel, U. Shah, C. Tan, A. Derkach, O. Lahoud, H. J. Landau, G. L. Shah, M. Scordo, D. J. Chung, S. A. Giralt, S. Z. Usmani, O. Landgren, M. Hultcrantz

Get full text

P886: AFRICAN AMERICAN PATIENTS WITH SMOLDERING MULTIPLE MYELOMA MAY HAVE A LOWER RISK OF PROGRESSION COMPARED TO WHITE PATIENTS by T. Akhlaghi, K. Maclachlan, N. Korde, S. Mailankody, A. Lesokhin, H. Hassoun, S. X. Lu, D. Patel, U. Shah, C. Tan, A. Derkach, O. Lahoud, H. J. Landau, G. L. Shah, M. Scordo, D. J. Chung, S. A. Giralt, S. Z. Usmani, O. Landgren, M. Hultcrantz

Get full text